Transfusion therapy resident survival guide: Difference between revisions
Line 31: | Line 31: | ||
|[[Cryoprecipitate]] | |[[Cryoprecipitate]] | ||
|❑ Bleeding patients with [[fibrinogen]] < 100 mg/dL<br>❑ Bleeding patients with [[Von Willebrand disease]] and factors [[Hemophilia A|VIII]] and [[Factor XIII deficiency|XIII]] deficiencies<br> '''Note''' - specific coagulation factor concentrates should be used to treat <br>patients with [[hemophilia]] , [[Von Willebrand disease]] | |❑ Bleeding patients with [[fibrinogen]] < 100 mg/dL<br>❑ Bleeding patients with [[Von Willebrand disease]] and factors [[Hemophilia A|VIII]] and [[Factor XIII deficiency|XIII]] deficiencies<br> '''Note''' - specific coagulation factor concentrates should be used to treat <br>patients with [[hemophilia]] , [[Von Willebrand disease]] | ||
|1 unit = fibrinogen (150 mg), factor VIII (80-120 u), von Willebrand factor (40-70 u), and factor XIII (20-30 u) | |1 unit = fibrinogen (150 mg), factor VIII (80-120 u), von Willebrand factor (40-70 u),<br> and factor XIII (20-30 u) | ||
<br>1 dose = ↑ circulating [[fibrinogen]] concentration by 50-100 mg/dL | <br>1 dose = ↑ circulating [[fibrinogen]] concentration by 50-100 mg/dL | ||
|- | |- | ||
Line 51: | Line 51: | ||
|- | |- | ||
|[[Leukoreduction|Leuko-reduced]] | |[[Leukoreduction|Leuko-reduced]] | ||
| | |❑ Patients at risk for [[Alloimmunity|HLA alloimunization]] | ||
:❑ Chronically transfused patients e.g., patients on chemotherapy<br> | |||
:❑ Patients for future organ transplants<br> | |||
❑ Patients with history of [[Transfusion reaction#Types of transfusion reactions|febrile non-hemolytic transfusion reactions]] | |||
| | | | ||
|} | |} |
Revision as of 20:34, 13 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
Overview
Blood transfusion is the process of transferring blood or blood products obtained from one person (donor) into the circulatory system of another (recipient).
Massive blood transfusion refers to transfusing a large volume of blood to a patient, especially in trauma patients with uncontrollable hemorrhage. Several definitions used in the past include:
- Transfusion of 20 units of red blood cells (RBCs) in 24 hours.[1]
- Transfusion of greater than 10 units of RBCs in 24 hours.[2]
Currently, it is more practical to identify patients in need of massive transfusion when greater than four red blood cell units is needed in one hour and an ongoing need for transfusion is predicted,[3] or when 50% of total blood volume is replaced within 3 hours. These situations often require the activation of massive transfusion protocols (MTP).[4]
Blood Products and Indications for Use
Blood Products | Indications | Dose |
---|---|---|
Packed red blood cells (PRBC) | ❑ Acute hemorrhage ❑ To ↑ O2-carrying capacity of blood in cases of end-organ ischemia |
1 unit of PRBC = ↑ Hemoglobin (Hb) concentration by 1 g/dL Transfuse slowly for the first 15 minutes Complete transfusion within 4 hours. |
Platelets (Plts) | In patients with thrombocytopenia (plts < 150,000 cells/uL) ❑ For prophylaxis (to prevent bleeding) ❑ For treatment (during active bleeding) Contraindications ❑ TTP/HUS, HIT, HELLP syndrome Click here for more information. |
1 apheresis unit = 6 units of plts in 250 - 300 mls of plasma 1 dose of apheresis unit = ↑ plt count by 30,000 - 60,000/uL |
Fresh frozen plasma | ❑ For bleeding patients due to multiple deficiencies of coagulation factors e.g., TTP/HUS, hepato-biliary diseases ❑ Warfarin-induced bleed (2nd choice) |
1 unit = 200 - 250 ml of plasma 1 ml of plasma = 1 u coagulation factors 1 unit contains 220 u coagulation factors 'A dose of 10-20 mL/kg (4-6 units) = 20% ↑ of circulating coagulation factors Note - specific coagulation factor concentrates should be used to treat patients with hemophilia , Von Willebrand disease, and antithrombin III deficiency |
Cryoprecipitate | ❑ Bleeding patients with fibrinogen < 100 mg/dL ❑ Bleeding patients with Von Willebrand disease and factors VIII and XIII deficiencies Note - specific coagulation factor concentrates should be used to treat patients with hemophilia , Von Willebrand disease |
1 unit = fibrinogen (150 mg), factor VIII (80-120 u), von Willebrand factor (40-70 u), and factor XIII (20-30 u)
|
Immunoglobulins | ||
Albumin | ||
Irradiated | ||
Cytomegalovirus-negative | ||
Leuko-reduced | ❑ Patients at risk for HLA alloimunization
❑ Patients with history of febrile non-hemolytic transfusion reactions |
Management
General Approach
Characterize the symptoms: ❑ Low red blood cell count or low hemoglobin level
❑ Low white blood cell count
❑ Low platelet count
| |||||||||||||||||||||||||||||
Obtain a detailed history: -❑ Review medical records
| |||||||||||||||||||||||||||||
Examine the patient: ❑ | |||||||||||||||||||||||||||||
Order laboratory tests: ❑ | |||||||||||||||||||||||||||||
Pre-transfusion preparation: ❑ | |||||||||||||||||||||||||||||
Low hemoglobin level | Coagulopathy | ||||||||||||||||||||||||||||
Low platelets | Coagulation factor deficiency | ||||||||||||||||||||||||||||
Indications | Indications | Indications | |||||||||||||||||||||||||||
Consider fresh frozen plasma | Consider cryoprepitate | Consider prothrombin complex concentrate | |||||||||||||||||||||||||||
Packed Red Blood Cells
Low hemoglobin concentration: ❑ | |||||||||||||||||||||||||||||||||||||||||
Review indications to transfuse: ❑ | |||||||||||||||||||||||||||||||||||||||||
Actively bleeding: ❑ Frank bleeding
❑ Occult bleeding
| |||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||
Asymtomatic | Symptomatic: ❑ | Symptomatic: ❑ | Asymptomatic | ||||||||||||||||||||||||||||||||||||||
Treat | Transfuse packed red blood cells | Treat | |||||||||||||||||||||||||||||||||||||||
Monitoring: ❑ | Manage complications: ❑ | Treat underlying cause: ❑ | |||||||||||||||||||||||||||||||||||||||
Managing Complications
Do's
Don'ts
References
- ↑ Wudel JH, Morris JA, Yates K, Wilson A, Bass SM (1991). "Massive transfusion: outcome in blunt trauma patients". J Trauma. 31 (1): 1–7. PMID 1986111.
- ↑ Malone DL, Hess JR, Fingerhut A (2006). "Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol". J Trauma. 60 (6 Suppl): S91–6. doi:10.1097/01.ta.0000199549.80731.e6. PMID 16763487.
- ↑ Moltzan CJ, Anderson DA, Callum J, Fremes S, Hume H, Mazer CD; et al. (2008). "The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework". Transfus Med. 18 (2): 112–20. doi:10.1111/j.1365-3148.2008.00846.x. PMID 18399845.
- ↑ Sihler KC, Napolitano LM (2009). "Massive transfusion: new insights". Chest. 136 (6): 1654–67. doi:10.1378/chest.09-0251. PMID 19995767.